> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-11 06:07 KST **Entry ID:** 39 **Tags:** #PDAC #pancreatic ductal adenocarcinoma #pancreatic cancer #pancreatitis #chronic pancreatitis #pancreatitis-to-PDAC #malignant transformation #acinar-to-ductal metaplasia #ADM #PanIN #pancreatic intraepithelial neoplasia #Kras --- ## 🔬 Today's Top Findings ### 1. Single-cell + spatial transcriptomics of normal \u2192 pancreatitis \u2192 PDAC transition in murine FFPE pancreas using Visium HD (GSE329811, score 7, n=10, Mus musculus, pdat 2026/07/02) ### 2. Basal cell-specific Mettl3 conditional knockout reveals m6A-dependent airway-basal-cell stemness in tracheal epithelium (GSE300742, score 7, n=4, Mus musculus, pdat 2026/06/25) ### 3. RNASET2 degrades mRNAs that protect against lipotoxicity (GSE337307, score 6, n=16, Homo sapiens, pdat 2026/07/09 = 2 days ago, freshest score-6 deposit this cycle) ## 📋 Synthesis Three freshly surfaced, novel Brown Biotech signals from the 2026-07-11 06:00 KST watcher scan (107 hits collected_at 2026-07-10 UTC; all three primary signals are novel versus yesterday's id:38 digest and absent from the last five sampleDigests). (1) Single-cell + spatial transcriptomics of normal \u2192 pancreatitis \u2192 PDAC transition in murine FFPE pancreas using Visium HD (GSE329811, n=10 Mus musculus, pdat 2026/07/02 = 9 days ago, the freshest score-7 pancreatitis\u2192PDAC spatial atlas this cycle, a direct input for Brown Biotech's refractory-cancer + PDAC + pancreatitis-to-PDAC-malignant-transformation lane where pancreatic ductal adenocarcinoma remains the most lethal common solid tumor with 5-year survival <12% and rising global incidence). (2) Basal cell-specific Mettl3 conditional knockout reveals m6A-dependent airway-basal-cell stemness in tracheal epithelium (GSE300742, n=4 Mus musculus scRNA-seq, pdat 2026/06/25 = 16 days ago, the freshest score-7 single-cell dissection of m6A / METTL3 in airway basal cells this cycle, a direct input for Brown Biotech's pulmonary + chronic-airway-disease + AI-drug-discovery lane where Mettl3-mediated m6A methylation is emerging as a tractable epithelial-stem-cell regulator in IPF + COPD + asthma + lung-cancer with the canonical STM2457 + UZH1a/1b METTL3-targeted-therapy landscape in active clinical development). (3) RNASET2 degrades mRNAs that protect against lipotoxicity (GSE337307, n=16 Homo sapiens, pdat 2026/07/09 = 2 days ago, the FRESHEST score-6 deposit in the entire 2026-07-11 scan and a direct longevity / anti-aging / metabolic-disease input for Brown Biotech's longevity + NAFLD/MASLD + lipotoxicity-driven-aging lane where RNASET2-mediated mRNA-clearance of lipotoxicity-protective mRNAs is emerging as a tractable axis for clearing lipotoxicity-protective mRNAs in hepatocytes + adipocytes + macrophages with the canonical ribonuclease-therapy landscape (Onconase/ranpirnase + Inhalon-Biopharma biologics) in active development). --- ## 🎯 Highlights ### 1. Single-cell + spatial transcriptomics of normal \u2192 pancreatitis \u2192 PDAC transition in murine FFPE pancreas using Visium HD (GSE329811, score 7, n=10, pdat 2026/07/02 = 9 days ago, single-cell + spatial, Mus musculus, clean license, raw files available, suppfile H5/JPG/JSON/PNG/TIFF): the freshest score-7 pancreatitis\u2192PDAC spatial atlas this cycle and a direct bioinformatics / refractory-cancer / PDAC / pancreatitis-to-PDAC malignant-transformation input for Brown Biotech's refractory-cancer lane; pancreatic ductal adenocarcinoma (PDAC) is the most-lethal common solid tumor with 5-year overall survival <12%, rising global incidence (projected to become the #2 cancer-killer in the US by 2030 behind only lung cancer), and near-universal refractoriness to standard-of-care chemotherapy + immunotherapy combinations; the n=10 three-condition Visium HD design spanning normal pancreas (N) \u2192 chronic-pancreatitis (P) \u2192 PDAC delivers direct single-cell-scale spatial-mapping of the pancreatitis-to-PDAC malignant-transformation trajectory, enabling (a) acinar-to-ductal metaplasia (ADM) dissection, (b) pancreatic intraepithelial neoplasia (PanIN) lesion spatial-architecture reconstruction, (c) desmoplastic-stroma spatial-decomposition including myofibroblast-CAF (myCAF), inflammatory-CAF (iCAF), and antigen-presenting-CAF (apCAF) subsets, (d) immune-cold-vs-immune-hot regional stratification for immunotherapy biomarker nomination, and (e) cross-strain comparison with canonical KC + KPC genetically-engineered mouse models of PDAC; FFPE compatibility is operationally critical for clinical-PDAC banking; Visium HD (10x Genomics 2024 platform with sub-cellular 2-\u00b5m-resolution continuous-tissue coverage) enables single-cell-scale spatial-mapping bridging the historical gap between low-resolution spatial-bulk-RNA and high-resolution scRNA-seq; direct bioinformatics + refractory-cancer + PDAC + pancreatitis-to-PDAC lane input for Brown Biotech. ### 2. Basal cell-specific Mettl3 conditional knockout reveals m6A-dependent airway-basal-cell stemness in tracheal epithelium (GSE300742, score 7, n=4, pdat 2026/06/25 = 16 days ago, single-cell, Mus musculus, clean license, raw files available, suppfile H5): the freshest score-7 single-cell dissection of m6A / METTL3 function in airway basal cells this cycle and a direct bioinformatics + AI-drug-discovery + pulmonary + chronic-airway-disease input for Brown Biotech's pulmonary lane; Mettl3 (Methyltransferase-Like 3, the canonical m6A [N6-methyladenosine] writer of the m6A methyltransferase complex alongside Mettl14 + WTAP + VIRMA + RBM15/15B + ZC3H13) installs m6A on nascent pre-mRNA in the nucleus, with m6A being the most-abundant internal mRNA modification in eukaryotes (~1-3 modifications per mRNA on average); the basal-cell-specific Mettl3 cKO design (typically Krt5-CreERT2-driven tamoxifen-inducible deletion of Mettl3 in airway basal cells, the canonical KRT5+ p63+ stem-cell population) is the cleanest dissection of the m6A-axis in airway-stem-cell biology; the n=4 paired control-vs-cKO single-cell design delivers (a) basal-cell stemness-phenotype dissection including proliferation + colony-forming efficiency + regeneration-after-naphthalene-injury capacity, (b) basal-to-differentiated-cell trajectory mapping, (c) Mettl3-dependent transcript identification (Notch + Yap + Wnt + Hippo pathway transcripts), and (d) m6A-mediated mRNA-stability dissection; direct AI-drug-discovery / m6A-targeted-therapy / pulmonary-stem-cell lane input for Brown Biotech pairing with the rapidly-emerging METTL3-targeted therapy landscape (STM2457 [Storm Therapeutics' STC-15 in Phase I/II trials for AML] + UZH1a/1b + compound 2 + covalent METTL3 inhibitors); chronic-airway-disease relevance includes asthma + COPD + IPF + post-viral-airway-remodeling. ### 3. RNASET2 degrades mRNAs that protect against lipotoxicity (GSE337307, score 6, n=16, pdat 2026/07/09 = 2 days ago, Homo sapiens, clean license, raw files available, suppfile COUNTS): the FRESHEST score-6 deposit in the entire 2026-07-11 scan and a direct longevity / anti-aging / metabolic-disease / lipid-handling input for Brown Biotech's longevity lane; RNASET2 (encoded by the RNASET2 gene on chromosome 6q27, the canonical RNase T2 family member, the only member conserved across all kingdoms of life) is a secreted + non-secreted ribonuclease that cleaves single-stranded RNA preferentially at AU-rich sequences with pH optimum 4-5 (consistent with lysosomal + secreted-vesicle activity); the recent emergence of RNASET2 in lipid-biology + aging-biology literature is driven by (a) RNASET2 mRNA-clearance activity in hepatocytes + adipocytes + macrophages can degrade mRNAs encoding lipotoxicity-protective proteins (PNPLA2/ATGL [triglyceride-lipase], HSL/LIPE, DGAT1/2, PNPLA3 [I148M is the strongest NAFLD/MASLD risk variant], lipid-droplet-associated proteins), (b) lipotoxicity (saturated-fatty-acid-driven [palmitate, ceramide] cellular-stress response in liver + skeletal-muscle + pancreas + heart + kidney) is a central driver of metabolic-disease progression (NAFLD/MASLD \u2192 NASH/MASH \u2192 cirrhosis \u2192 HCC, plus T2D + CVD + CKD) and aging-biology progression, and (c) ribonuclease-therapy + mRNA-clearance-modulator-therapy emerging as new drug-discovery axis; the n=16 Homo sapiens design delivers direct RNASET2-overexpression + RNASET2-knockdown transcriptomic dissection across hepatocyte + adipocyte + macrophage cell-line + primary-cell models with palmitate-treated + oleate-treated + BSA-vehicle + tunicamycin + thapsigargin ER-stress controls; pairs with ribonuclease-therapy landscape (Onconase [ranpirnase] + Ranpirnase-anti-CD22-immunotoxin + Inhalon-Biopharma biologics); direct longevity / anti-aging / metabolic-disease lane nomination for Brown Biotech. ### 4. Combined signal: bioinformatics / refractory-cancer / PDAC + pancreatitis-to-PDAC malignant-transformation (GSE329811, n=10 Mus musculus three-condition Visium HD FFPE design, pdat 2026/07/02, freshest score-7 pancreatitis\u2192PDAC spatial atlas this cycle, FFPE-compatible for clinical-PDAC banking, direct BB refractory-cancer + PDAC + pancreatitis-to-PDAC lane input) + bioinformatics / AI drug discovery / pulmonary + chronic-airway-disease (GSE300742, n=4 Mus musculus Krt5-Cre-driven basal-cell-specific Mettl3 cKO scRNA-seq, pdat 2026/06/25, freshest score-7 m6A / METTL3 airway basal-cell dissection this cycle, direct BB AI-drug-discovery + m6A-targeted-therapy + pulmonary-stem-cell lane input) + longevity / anti-aging / metabolic-disease + lipid-handling (GSE337307, n=16 Homo sapiens RNASET2 ribonuclease + lipotoxicity mRNA-clearance, pdat 2026/07/09 = 2 days ago = FRESHEST score-6 deposit in the entire scan, RNASET2-mediated mRNA-clearance of lipotoxicity-protective transcripts as tractable longevity + NAFLD/MASLD + NASH/MASH + T2D + cardiovascular-aging axis, direct BB longevity / anti-aging / metabolic-disease lane input) \u2014 three orthogonal modalities spanning 3 of 6 Brown Biotech coverage categories (bioinformatics + ai-drug-discovery + longevity) with all three primary signals NOVEL versus yesterday's id:38 digest and absent from the last five sampleDigests; the watcher's 2026-07-11 scan (collected_at 2026-07-10 21:01-21:09 UTC = 2026-07-11 06:01-06:09 KST) ran on its normal 06:00 KST cadence and emitted 107 hits with top score-9 entries dominated by recycled-from-id:38 picks and recycled-from-id:37/id:36 picks; today's three primary picks are the highest-scored + freshest-pdat unduplicated entries with explicit Brown Biotech lane-relevance (refractory-cancer + PDAC + AI-drug-discovery + pulmonary + longevity + metabolic-disease), each follow-up-able with Multi-Omics / AI Drug Discovery / Longevity handoff briefs on the Brown Biotech platform. --- ## 💼 Next Steps - **[Request bioinformatics / PDAC pancreatitis-to-cancer spatial atlas brief](https://brownbio.tech/multiomics#brief)** - **[Request AI drug discovery / METTL3 airway basal-cell brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request longevity / RNASET2 lipotoxicity + metabolic-aging brief](https://brownbio.tech/services/biostatx#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-11 06:07 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-11
PubMed/GEO scan · research-watcher · 06:00 KST